Get the Stockscreener App
3.00
4.90%
0.14
Aadi Bioscience Inc stock is traded at $3.00, with a volume of 247.87K.
It is up +4.90% in the last 24 hours and up +30.43% over the past month.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
See More
Previous Close:
$2.86
Open:
$2.8
24h Volume:
247.87K
Relative Volume:
0.95
Market Cap:
$71.23M
Revenue:
$23.26M
Net Income/Loss:
$-63.41M
P/E Ratio:
-1.2295
EPS:
-2.44
Net Cash Flow:
$-64.56M
1W Performance:
+25.52%
1M Performance:
+30.43%
6M Performance:
+71.43%
1Y Performance:
+52.28%
1-Day Range:
$2.7519
$3.04
1-Week Range:
$2.07
$3.60
52-Week Range:
$1.21
$3.60
Aadi Bioscience Inc Stock (AADI) Company Profile
Name
Aadi Bioscience Inc
Sector
Industry
Phone
424-473-8055
Address
17383 SUNSET AVENUE, PACIFIC PALISADES
Compare AADI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AADI
Aadi Bioscience Inc
|
3.00 | 71.23M | 23.26M | -63.41M | -64.56M | -2.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.57 | 105.01B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.17B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.39 | 37.48B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 30.94B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.13 | 27.15B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aadi Bioscience Inc Stock (AADI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Aadi Bioscience Inc Stock (AADI) Latest News
Aadi Bioscience Enters Into Multiple Strategic Agreements, Including $100M Stock Purchase and License Agreement - Defense World
Aadi Bioscience Leads 3 Promising US Penny Stocks - Simply Wall St
Aadi Bioscience rockets 72% on key updates - MSN
Aadi Bioscience’s Strategic Agreements and Funding Moves - Yahoo Finance
Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini
Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - Scrip
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday? - Benzinga
Aadi Bioscience stock soars on licensing and sale deals - Investing.com India
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - Marketscreener.com
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing - Yahoo Finance
Kaken Pharmaceutical Co., Ltd. agreed to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - Marketscreener.com
Clinical Trials News Live Feed - StockTitan
Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - MarketBeat
AADI Enlists NY Court To Enforce Cancer Drug Award - Law360
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Decreases By 8.8% - MarketBeat
GSA Capital Partners LLP Cuts Stake in Aadi Bioscience, Inc. (NASDAQ:AADI) - Defense World
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates - MSN
US Penny Stocks Under $90M Market Cap To Watch - Simply Wall St
BML Capital Management LLC Takes $4.12 Million Position in Aadi Bioscience, Inc. (NASDAQ:AADI) - MarketBeat
Aadi Bioscience Reports Q3 2024 Earnings and Growth - TipRanks
Aadi Bioscience Faces Potential Financial Strain from Securities Class Action Risks - TipRanks
Aadi Bioscience earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Aadi Bioscience Q3 Sales Surge 21% YoY, FYARRO Growth Drives Strong Performance | AADI Stock News - StockTitan
Aadi Bioscience to Report Third Quarter 2024 Results and Corpora - GuruFocus.com
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update - BioSpace
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Resu - GuruFocus.com
Aadi plunges 36% as phase 2 trial for solid tumors asset unlikely to meet goal - MSN
Aadi Bioscience CEO sells shares worth $18,796 By Investing.com - Investing.com South Africa
Aadi Bioscience CEO sells shares worth $18,796 - Investing.com India
Wilson Sonsini Defeats $341 Million Arbitration Claim Against Aadi Bioscience - Wilson Sonsini
DADA’s 2023 Market Dance: Down -64.46% – Time to Invest? - The InvestChronicle
Pacer Advisors Inc. Sells 1,089 Shares of Analog Devices, Inc. (NASDAQ:ADI) - Defense World
A Glimpse Into The Expert Outlook On Analog Devices Through 8 Analysts - Benzinga
Nippon Life Global Investors Americas Inc. Makes New $1.10 Million Investment in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Market Highlights: Aditxt Inc (ADTX) Ends on a Low Note at 0.38 - The Dwinnex
Applied Dna Sciences Inc (APDN) presents a great opportunity, but the stock is slightly overvalued - US Post News
‘It felt like the world had ended’; Aadi Adeel on his father’s passing - TheCurrrent.pk
Analog Devices (NASDAQ:ADI) Downgraded to "Hold" at Truist Financial - MarketBeat
Magnetar Financial LLC Lowers Stake in ADMA Biologics, Inc. (NASDAQ:ADMA) - MarketBeat
Intech Investment Management LLC Trims Holdings in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
There is no way Aditxt Inc (ADTX) can keep these numbers up - SETE News
AE Wealth Management LLC Has $4.39 Million Stock Holdings in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Edgestream Partners L.P. Acquires New Stake in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Healthcare stock jumps after it enters in an agreement to set up woman and children hospital - Trade Brains
Adairs Ltd Director Increases Share Holdings - TipRanks
Profund Advisors LLC Grows Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Quest Investment Management LLC Cuts Holdings in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Summit Trail Advisors LLC Buys 264 Shares of Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Sei Investments Co. Increases Stock Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Chronicle-Tribune
Aadi Bioscience Inc Stock (AADI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aadi Bioscience Inc Stock (AADI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lennon David James | CHIEF EXECUTIVE OFFICER |
Oct 03 '24 |
Sale |
1.94 |
9,689 |
18,797 |
22,869 |
0.10%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):